Abstract The pro-apoptotic P2X 7 receptor regulates growth of epithelial cells. The objectives of the study were to understand P2X 7 gene transcription; to identify the active promoter and the transcription initiation site (TpIS); and to begin understanding regulation of P2X 7 gene transcription. Experiments in vitro utilized normal and cancerous cultured human uterine cervical epithelial cells, and HEK293 cells overexpressing P2X 7 -luciferase reporters. Experiments in vivo used surgical specimen of normal and cancerous uterine cervix. Assays involved DNA, RNA, and protein techniques. (a) The P2X 7 TpIS was localized to adenine (+1) at nt 1683 of the human P2X 7 gene [GenBank Y12851]), with a TTAAA sequence at nt −32/−28 and an active promoter region within nt −158/+32. (b) P2X 7 transcription was found to be regulated by two enhancers located at nt + 222/+232 and +401/+573 regions downstream of the active P2X 7 promoter. (c) The putative enhancer regions formed four DNA-protein complexes. (d) P2X 7 transcription was found to be controlled by hypermethylated cytosines at cytosine-phosphodiesterguanosines (CpG) that cluster or co-localize with the enhancers' sites. (e) We identified nine CpGs as inhibitory cis elements, and three CpG sites that are hypermethylated in cultured cervical epithelial cells and in cervix epithelia in vivo. (f) In cancer cervical cells, the degree of hypermethylation of the CpG sites was greater than in the normal cervical cells. Expression of the P2X 7 receptor is controlled by hypermethylated CpGs that flank transcription enhancers located within a 547-nt region downstream of the promoter.
Introduction
Apoptosis is a regulated homeostatic process of selective cell deletion [1] [2] [3] , and it controls the growth of cells [4] . Dysregulation of apoptotic cell death has been implicated in states of disease and in the neoplastic transformation [5, 6] . Among the pro-apoptotic systems that operate in various types of tissues, including epithelia, the P2X 7 receptor mechanism is an important mechanism because the receptor is expressed in proliferating cells [7] , and P2X 7 -induced apoptosis controls physiologically the growth of cells [8, 9] . Recent data showed lesser expression of the P2X 7 receptor in cancer cells of epithelia derived from ectodermal, urogenital sinus, and the distal paramesonephric duct tissues [7, [10] [11] [12] [13] [14] , suggesting that reduced expression of the receptor may be related to the development of those cancers.
The P2X 7 receptor is a membrane-bound, ligandoperated channel [15] [16] [17] . The natural ligand of the receptor is ATP [15, 16] which is present in the extracellular fluid of epithelial cells at concentrations that can activate the receptor [4, 8, [18] [19] [20] [21] . Binding of ATP to the P2X 7 receptor can activate various cell-specific signaling cascades, including the IL-1β [22] , TNFα-TRAIL [23] , and the p38, JNK / SAPK [24] , and NF-κB cascades [25] . However, a unique effect of activation of the P2X 7 receptor is formation of pores in the plasma membrane [16] . In uterine epithelial cells [8, 11, 17] and in mouse keratinocytes [9] , formation of P2X 7 receptor pores induces apoptosis by a mechanism that involves uncontrolled influx of Ca 2+ via P2X 7 -pores and activation of the mitochondrial caspase-9 pathway [8, 11] .
Central to the ability of ATP to induce apoptosis via the P2X 7 mechanism is the degree of cellular expression of the P2X 7 receptor [17] . For instance, in human uterine cervical epithelial cells [8] and in mouse keratinocytes [9] , apoptosis induced by treatment with ATP or with the P2X 7 -specific agonist 2′,3′-0-(4-benzoylbenzoyl)-adenosine 5′-triphosphate (BzATP) was less in cancer than in normal cells, and the differences in agonist-induced apoptosis correlated with cellular expression of the receptor [11] [12] [13] . One of the mechanisms that explain the lower expression of P2X 7 receptor in cancer cervical cells is greater instability of the P2X 7 transcript in the cancer cells [13] . However, recent preliminary data from the author's lab also suggested modulation of transcription in cancer cells. Until recently, little was known about the regulation of transcription of the P2X 7 gene. The human P2X 7 gene is localized within a 55-kb region of chromosome 12q24; it has 13 exons and it encodes a 595-amino-acid protein [26] . Previous studies reported P2X 7 promoter activity within a 2-kb DNA segment of the 5′ of the gene [26, 27] , but the location of the active promoter and the transcription initiation site (TpIS) were unknown. Five single nucleotide polymorphisms were identified within the 5′ 2 kb DNA segment of the gene (sites −298, −762, −838, −1140, and −1269 [relative to exon 1]), but none were associated with a specific ATP response phenotype [28] . Furthermore, previous sequencing efforts have identified numerous P2X 7 variations and had proposed linkage to human disease, but at present, there is no consensus about their biological role [29] .
The major objective of the present study was to better understand P2X 7 gene transcription. Specific objectives were to identify the active promoter; to define the TpIS; and to begin understanding regulation of P2X 7 gene transcription. An improved understanding of the regulation of P2X 7 gene expression could be important for our understanding of the development of cancers because defective apoptosis may lead to cancer [30] [31] [32] . The experiments used, as a model, human epithelial uterine cervical cells. The physiological pro-apoptotic role of P2X 7 in these cells was previously demonstrated [7, 8, 13] . Previous studies in cervical cells have also identified tumor suppressor genes [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] and apoptosis-related genes [35, 39, 43, 44, [46] [47] [48] [49] that are regulated by changes in DNA methylation. However, until recently, little was known about the effects of DNA methylation on P2X 7 gene expression.
Methods

Cell cultures
Primary cultures of human ectocervical-vaginal epithelial cells (hEVEC), a well-characterized model of the normal human ectocervical epithelium, were generated from discarded normal ectocervical-vaginal tissues [4] . Human cervical epithelial cancer cell lines (Caski, HeLa, Siha, and HT3), and human embryonic kidney 293 cells (HEK293), which lack endogenous expression of P2X 7 [11] , were obtained from the ATCC. Cell culture conditions were described [4, 11] .
Elucidation of the promoter region
HindIII-tailed sense primers and the NcoI-tailed antisense primers (InVitrogen, Carlsbad CA) that were used for the elucidation of the promoter region of the human P2X 7 gene (GenBank Y12851) are shown in Table 1 . The corresponding cDNA fragments were synthesized by PCR using human genomic DNA. The PCR fragments were digested with HindIII and NcoI and ligated into pGL3 enhancer vector (Promega, Madison, WI) with HindIII and NcoI sites using Rapid DNA Ligation Kit (Roche, Indianapolis, IN). Reporters in this experiment and in all the experiments described below were confirmed by sequencing.
Control plasmids containing the pGL3 luciferase enhancer vector (5064 nt) or test plasmids (P2X 7 -luciferase) were transfected into subconfluent cultured HEK293 cells that were plated 14 h earlier in six-well plates at a density of 2.5×10 5 cells per well. The culture medium was replaced with fresh medium plus 100 μl serum-free medium per well, containing 2.5 μl Fugene 6 (Roche) and 750 ng DNA of the control or test vectors. For luciferase activity determinations cells were cotransfected with Renilla luciferase and 30 ng of the pRL-CMV vector (Promega) [13] . At the completion of incubations cells were harvested and maintained in lyses buffer for 24 h (Promega); Firefly and Renilla luciferase activities were measured consecutively by using Dual-Luciferase Reporter Assay System (Promega), and luciferase activity was determined in terms of Fluc/Rluc. For determinations of changes in P2X 7 and Firefly luciferase (Fluc) mRNA, cells were lysed followed by RNA extraction. P2X 7 and Fluc mRNA levels were determined by real-time PCR (qPCR) relative to cytokeratin-18 (CK-18) or GAPDH, and expressed in terms of the threshold cycle of fluorescence (C t ), using our described methodology [12, 13] . Primers for P2X 7 , Fluc, CK-18 and GAPDH were described [7, [11] [12] [13] .
Elucidation of the transcription initiation start site A modified 5′ rapid amplification of cDNA ends method (5′-RACE) was used. Primers (InVitrogen) are shown in Tables 2 and 3 . Cloning, by reverse transcription (RT), was carried out at 55°C (total of 20 μg RNA per reaction), using Invitrogen SuperScript™ III Reverse Transcriptase (InVitrogen). Biotin-labeled primers were used for RT to produce cDNA, and the biotin-labeled cDNA was combined with Dynabeads in order to concentrate the cDNA product and facilitate its purification. To this aim, the RT reaction was mixed with 40 μl Dynabeads M-280 streptavidin (Invitrogen) at 25°C for 30 min; beads were washed in buffer containing 10 mM Tris pH 7.5, 1 mM EDTA, and 2 M NaCl, and the beads-attached cDNA was tailed using Terminal Transferase (Promega) with dATP at 37°C for 20 min and at 70°C for 10 min. PCR was done with a primer pair of anchor TTT and the gene-specific nested primers. A second PCR was done with the anchor primer and the nested HindIII antisense primer using the first PCR products diluted 100-fold. The resulting cDNA fragment was cloned into pGL3 enhancer vector with HindIII site, and confirmed by sequencing. The primary TpIS was identified from the sequence, beginning with adenine, and designated as site +1 (nt 1683 of the published human P2X 7 gene sequence [GenBank Y12851]).
Oligonucleotides-directed mutagenesis of regions of interest within the promoter region [13] utilized the pGL3 enhancer vector reporter containing fragment −158 to +32 and the PCR method. Regions of interest and mutations were as follows: nt −1 to +3 (CATT/GTAA); nt −31 to −30 (TA/CC); nt −73 to −70 (AGGG/TATA); and nt −102 to −101 (TT/CC). Primers are shown in Tables 2 and 3 .
Mutagenesis of CpG sites
Mutations in the CpG sites within the 547-nt region downstream of the P2X 7 promoter were as follows: +211/+212 (CG/AA), +257/+258 (CG/TT), +278/+279 (CG/TT), +319/ +320 (CG/AT), +330/+331 (CG/AT), +424/+425 (CG/TT), +461/+464 (CGCG/ATTA), +453/+454 (CG/TT), +475/+476 (CG/TT), +498/+499 (CG/TT), and +548/+549 (CG/TT). Primers are shown in Table 4 . cDNA fragments composed of the P2X 7 active promoter attached with the downstream 547-nt region containing the wild-type or mutant sequences were inserted into a luciferase vector and transfected into HEK293 cells. Promoter activity was determined in terms of luciferase activity. TTT  TTA  AGC  TTA  AGA  TGT  GAA  GCC  AGG  ATC  G  −1179  TTT  TTA  AGC  TTG  GAT  CAA  GCC  AGC  TGTA  −698  TTT  TTA  AGC  TTG  GTG  GTG  TCC  CTC  ACT  GAA  T  −399  TTT  TTA  AGC  TTG  GGG  CTG  AAT  AAA  GGG  TTG  T  −204  TTT  TTA  AGC  TTA  ATG  CCC  ATC  CTC  TGA  ACA  C  −158  TTT  TTA  AGC  TTG  CCA  GCT  GGG  GTG  AGG  TCA  TCT  G  −122  TTT  TTA  AGC  TTT  AGG  ACT  TGG  CGC  TTC  TTG  T  −73  TTT  TTA  AGC  TTA  GGG  CCC  GCC  CCA  ACT  CTG  CAG  −53  TTT  TTA  AGC  TTA  GTC  ATT  GGA  GGA  GCT  TGA  AGT The previously described method [7, 12] utilized rabbit polyclonal anti-P2X 7 receptor antibody (primary, from Alomone Laboratories, Jerusalem, Israel) [9] and goat anti-rabbit Alexa Fluro 594 (secondary, from Invitrogen) [9] . Immunofluorescence was captured in a fluorescence microscope Nikon Eclipse 80i (Nikon, Melville NY) [11] . Image analysis of the immunofluorescence data was done as described [11] and expressed in terms of average pixel density per cell.
Apoptosis assays
Apoptosis was quantified by using Roche Cell Death Detection ELISA Kit (Roche) [11] .
In vitro methylation assays Control (pGL3 luciferase enhancer vector) or test plasmids (P2X 7 -promoter-luciferase) were methylated in vitro prior to transfections by incubations with the CpG-Methylase M. SssI (which adds a methyl group in cytosine residues) according to the manufacturer's protocol (New England Biolabs, Ipswich, MA).
Electrophoretic mobility shift assay A pGL3 enhancer Vector with an insert of the P2X 7 promoter was used as the template, and assays were performed using LightShift® Chemiluminescent EMSA Kit (Pierce, Rockford, IL). Briefly, biotin-labeled fragments were amplified by PCR with one of the primers listed in Table 5 . After amplification, P2X 7 promoter fragments were separated on 1.5% agarose gel and extracted using the Agarose Gel Extraction Kit (QIAGEN). The binding reaction was performed for 30 min at room temperature using the electrophoretic mobility shift assay (EMSA) kit system in a total volume of 20 μL containing 2 μl binding buffer, 0.5 μg of HeLaScribe Nuclear Extract (Promega), 40 fmol biotin-labeled oligonucleotide, and 1 μl poly (dIdC). DNA-protein complexes formed were fractionated by electrophoresis over 4% polyacrylamide gels in 1× Trisboric acid-EDTA buffer. Gels were electrophoretically transferred at 100 V for 1 h on ice to a positively charged nylon membrane and immediately cross-linked with a UV transilluminator. Streptavidin-horseradish peroxidase conjugate and the LightShift Chemiluminescent Substrate (Pierce) were used to detect the biotin end-labeled DNA, and the nylon membranes were exposed to X-ray film for 3 min for detection of possible DNA-protein binding reactions.
Human tissues
Discarded human uterine tissues were used for DNA methylation analysis. GGT GTA GTC TGC GGT GTC AA nested HindIII-tailed (located at Exon-2) CCG CTA AGC TTG CTT GTC ACT CAC CAG AGC A paraffin embedded blocks that were prepared by the Department of Pathology initially to establish the patient's diagnosis. For the assays, additional parallel 10-μm sections were cut and slides were made according to standard procedures. For each case, an H&E stained slide was used to identify normal or cancerous cervical epithelial regions. Tissue epithelial fragments were obtained from parallel regions of non-stained slides by microdissection. The tissue material was dispersed into 100 μl digestion buffer (50 mM Tris pH 8.5, 0.5% Tween 20, 200 μg/ml proteinase-K), incubated at 42°C overnight, and proteinase-K was inactivated by incubation at 80°C for 10 min. The data presented in this paper are considered preliminary proof-of-concept, and no formal Power Analysis was performed to determine the number of tissues to be included in testing any specific hypotheses. No attempt was made to categorize results by patients' ethnic origin or race.
DNA methylation analysis
Assays used the method of combined bisulfite restriction analysis (COBRA) which employs restriction enzyme digestion to reveal methylation-dependent sequence differences in PCR products of sodium bisulfite-treated DNA [50] . Briefly, bisulfite-treated, genomic DNA unmethylated cytosines are converted to thymidines whereas methylated cytosine residuals are retained as cytosines. DNA segments of interest are amplified using PCR primers that do not contain CpG dinucleotides so that the amplification step does not discriminate between templates by their original methylation status. The PCR products are digested by restriction enzymes that recognize sequences containing CpG. Cleavage occurs if the CpG sequence has been retained during the bisulfite conversion according to the methylated status of the cytosine residue. The digested PCR products are resolved and separated by gel electrophoresis and stained with ethidium bromide.
Cloning of CpG-rich regions downstream of the promoter
Patterns of methylation were determined within a 547-bp region of nt +26/+573 (relative to the subsequently defined TpIS, nt + 1; Fig. 1 ). The region of interest was arbitrarily divided to three segments with partial overlaps, designated segment 1 (nt +26/+247), segment 2 (nt +223/+399), and segment 3 (nt +352/+573). Primers are shown in Table 6 . PCR conditions (annealing temperature) and the restriction enzyme used were as follows: segment 1 56°C (MaeII); Segment-2 56°C (MaeII); segment 3 59°C (BstUI).
Evaluation of DNA Methylation Genomic DNA was extracted from cultured cells and from human tissues using DNA purification kit (Promega). To convert CpG nonassociated cytosines to uracil (and thymidines), 1 μg of genomic DNA was denatured with 2 M NaOH at 37°C for 10 min; 30 μl of 10 mM hydroquinone were added and the solution was incubated with 3 M sodium bisulfite (pH 5) at 53°C for 16 h in darkness. After treatment, DNA was purified by DNA clean up kit (Promega). The solution was incubated with 2 M NaOH at room temperature and precipitated with 100% ethanol, washed with 70% ethanol, and resuspended in 20 μl of distilled water. The bisulfitetreated DNA was amplified by PCR (95°C 5 min/95°C 30 s/55-59°C 45 s/and 72°C 45 s, 37 cycles). PCR products were digested with restriction enzymes and separated in 6% polyacrylamide gel at 4 W for 3 h and the amplified products were checked for accuracy by sequencing. Positive control for the DNA methylation experiments was human placental genomic DNA treated with the CpG-Methylase M.SssI and the negative control was water. DNA methylation was determined from the polyacrylamide gel pictures in terms of samples showing de novo appearance of a low MW band, corresponding to a cleaved band at a previously methylated site. The degree of methylation was determined by densitometry in terms of the intensity of the cleaved fragment (lower MW band) relative to the density of the non-methylated plus the methylated bands (lower plus higher MW bands). Densitometry was done as described [11] .
To confirm the efficacy of the bisulfite method for converting genomic DNA cytosines (but not methylcytosines) to uracils, bisulfite-treated genomic DNA was amplified with primers for Segments 1 and 2. PCR products were purified with PCR purification kit (QIAGEN) and cloned into vector pCR II-TOPO (Invitrogen). Subclones were transformed into E. coli bacteria type BL21 and cultured overnight at 37°C. Plasmid-containing PCR products were extracted with miniprep kit (Promega) and sequenced. The results (not shown) confirmed that all genomic DNA cytosines converted to uracils, except methylcytosines.
Data analysis
Data were analyzed using GraphPad Instat (GraphPad Software Inc., San Diego, CA). Significance of differences Fig. 1 Sequence of the 5′ region of the human P2X 7 , containing the active promoter (white symbols on black background, nt −158/+32); a 547-nt CpG-rich region (underlined, nt +26/+573) downstream of the promoter; Exon 1 (underlined and italics, nt +92/+216); and the proximal part of intron-1 (distal to Exon 1, underlined, beginning at nt +217). Nucleotides were numbered relative to the Transcription Initiation Start Site (TpIS; +1; nt 1683 according to GenBank Y12851). TpISs-and TATA-like sequences within the active promoter bases/regions are bolded and doubly underlined. CpG dinucleotides are bolded and doubly underlined. Vertical thick empty arrows point to MaeII-sensitive CpG sites (nt +193/+194, +211/+212, and +330/+331). The vertical thick-filled arrow points to a BstUI-sensitive CpG-CpG site (nt +461/+462 and +463/+464). For DNA methylation experiments the 547-nt CpG-rich region was subdivided into segment 1 (nt +26/ +247), segment 2 (nt +223/+399), and segment 3 (nt +352/+573) between groups was estimated by t test, or by one-way or two-way ANOVA with Tukey-Kramer Multiple Comparisons post test analysis.
Supplies
All chemicals, unless specified otherwise, were obtained from Sigma Chemicals (St. Louis, MO).
Results
Elucidation of the active promoter region
To define the active promoter region and the TpIS, a series of cDNA fragments were generated encompassing a 1.7-kb DNA segment at the 5′ region of the human P2X 7 gene. Nucleotides were numbered relative to the subsequently elucidated TpIS (+1), which corresponds with nt 1683 of the human P2X 7 gene (GenBank Y12851). Initial experiments included cDNA fragments ranging from −1664/+32 to −53/+32 nt ( Figs. 1 and 2a) . The cDNA fragments were inserted into a luciferase vector, and the P2X 7 -luciferase reporter was transfected into HEK293 cells which lack endogenous expression of the P2X 7 . Significant promoter activity was found in fragments ranging from −1664/+32 to −158/+32 nt, while shorter fragments lacked significant promoter activity (Fig. 2a) . A cDNA fragment of −1179/−380 nt lacked significant promoter activity, suggesting that there is little promoter activity upstream of nt −380. Since maximal promoter activity was found in experiments using the −158/+32 nt fragment (Fig. 2a) , the data suggested location of the active promoter of the human P2X 7 gene in the −158/+32 nt region.
The TpIS was elucidated using the modified 5′ RACE method. By sequencing, two possible TpISs were found upstream of the subsequently defined TpIS: adenine bases at +1 nt and −73 nt (Fig. 1) . To determine which of the two is important, the TpIS-corresponding regions were mutated as (−1) CATT to GTAA, and (−73) AGGG to TATA (Fig. 2b) . Fragments carrying the mutated regions were inserted into the luciferase vector and transfected into HEK293 cells. The results showed 70% luciferase activity in the (−73)AGGG→TATA construct but only 30% luciferase activity in the (−1)CATT→GTAA construct (Fig. 2b) . Sequence analysis also suggested two TATAlike sequences located upstream of the subsequently defined TpIS: TTAAA at −32 nt, and TTATC at −102 nt (Fig. 1) . Mutation analysis revealed 50% luciferase activity in the (−32)TTAAA→TCCAA construct and no change in luciferase activity in the (−102)TTATC→CCATC construct (Fig. 2b) . Collectively, these data suggest a functionally important TpIS at site +1 nt and a TATA-like sequence TTAAA at site −32 nt.
Regions distal to the TpIS inhibit transcription
Sequence analysis of the human P2X 7 gene (GenBank Y12851) downstream of the active promoter revealed an unusually high concentration of cytosine-phosphodiesterguanosine (CpG) dinucleotides sites in the +26 to +573 nt region (Fig. 1 ). This region of 547 nt contains 20 CpG sites, in contrast to the −158/+32 190-bp active promoter region, which contains only 4 CpG sites (Fig. 1) . Since changes in methylation of cytosines within CpG sites can modulate gene function [51] , we tested the hypothesis that changes in the methylation status of CpG sites in the region downstream of the active promoter can regulate P2X 7 transcription.
A construct containing the fragment −158/+573 resulted in less transcription compared to the −158/+32 construct (Fig. 2c) . To ascertain that the changes in Fluc/Rluc shown in Fig. 2c (upper panel) are not artifactual, the experiment was repeated using as endpoint changes in Fluc/GPDH mRNA. The data were similar (Fig. 2c, lower panel) indicating that cis regulatory elements contained within the +33 to +573 nt region downstream of the active P2X 7 promoter inhibit transcription.
Aza-dC effects on P2X 7 mRNA levels To determine whether changes in DNA methylation modulate P2X 7 gene transcription, cultured cervical cells were treated with the de-methylation agent 5-aza-2′-deoxycytidine (Aza-dC), and effects on P2X 7 mRNA steady-state levels were measured. For experiments, cells were treated with 1 μM Aza-dC, which in preliminary experiments exerted near maximal effects (not shown). -GGA TTT GGG GAG GAT TTAGATT-3  Reverse-CAA CCT AAC ACC GTT TCCTCTT-3  Segment 3 Forward-GGG AGG GAG GAA GTA GTA GTA GGT A Reverse-TCA AAT ACC AAC ATA ATC ACC AAA C Table 6 Primers for experi ments using segments [1] [2] [3] Baseline levels of P2X 7 mRNA steady-state levels (relative to CK-18) were higher in the normal hEVEC than in the HeLa cancer cervical epithelial cells (Fig. 3a) , confirming previous reports [7, 11] . Treatment with AzadC increased P2X 7 mRNA both in hEVEC and in HeLa cells (Fig. 3a) . The effect was time-dependent, and increases in P2X 7 mRNA were observed already 18-24 h after treatment (Fig. 3a) . In hEVEC cells, levels of P2X 7 mRNA continued to increase; in HeLa cells P2X 7 mRNA levels plateaued after 24 h and began to decrease afterwards, but remained elevated compared to baseline for at least 72 h after the start of treatment (Fig. 3a) .
Aza-dC effects on P2X 7 protein levels Aza-dC effects on P2X 7 protein were determined in terms of changes in cellular immunoreactivity to the anti P2X 7 antibody. In non-treated hEVEC cells, staining with the anti P2X 7 receptor antibody revealed homogenous P2X 7 immunoreactivity (Fig. 3b, insert) , and treatment with 1 μM Aza-dC for 48 h increased the P2X 7 immunoreactivity significantly (Fig. 3b) . A similar effect was seen in HeLa cells (not shown). Image analysis of P2X 7 immunofluorescence density in Aza-dC-treated cells revealed a twofold increase after 48 h of treatment in P2X 7 immunoreactivity for both the hEVEC and HeLa cells (Fig. 3b) .
Aza-dC effects on baseline and P2X 7 -mediated apoptosis Baseline apoptosis, which is induced paracrinologically by ATP secreted by the cultured cells [8] , was twofold higher in hEVEC cells than in HeLa cells (Fig. 3c) , confirming previous reports [8, 11] . Treatment with the P2X 7 -receptorspecific agonist BzATP increased apoptosis 2.5-fold in Fig. 2 a-b . Elucidation of the P2X 7 Active Promoter Region. a cDNA fragments corresponding to regions within a 1.7-kb DNA segment of the 5′ region of the human P2X 7 gene were inserted into luciferase vector; the P2X 7 -luciferase reporters were transfected into HEK293 and P2X 7 promoter activity was determined in terms of changes in luciferase activity (Fluc/Rluc). Data (means ± SD, three to five experiments in triplicates) were normalized (=1) to Fluc/Rluc recorded in cells transfected with empty vector. *p<0.01 compared to the rest. b Confirmation of P2X 7 TpIS. Two potential TpISs and their related TATA-like regions were mutated and effects on P2X 7 transcription were determined as in a (means±SD, three to five experiments in triplicates). *p<0.01 compared to −158/+32. c P2X 7 transcription is modulated by effectors downstream of the active promoter. P2X 7 −158/+32 or −158/+573 luciferase reporters were transfected into HEK293 cells and P2X 7 promoter activity was determined in terms of changes in luciferase activity (Fluc/Rluc, upper panel) or in terms of changes in Fluc/GAPDH mRNA (lower panel). Shown are means (±SD) of one to three experiments in triplicates. Data of Fluc/GAPDH mRNA were normalized (=0) to those recorded in cells transfected with empty vector. *p<0.01 hEVEC cells but it had no significant effect in HeLa cells (Fig. 3c) . Treatment with Aza-dC increased mildly baseline apoptosis in hEVEC cells, and significantly (twofold) baseline apoptosis in HeLa cells (Fig. 3c) . In hEVEC cells pretreated with Aza-dC, co-treatment with BzATP resulted in greater apoptosis than in cells treated only with BzATP, but the effect was mild (Fig. 3c) . In contrast, in Aza-dCpretreated HeLa cells co-treatment with BzATP resulted in 2.5-fold greater apoptosis than in cells treated only with BzATP, and the degree of apoptosis was nearly that observed in hEVEC cells under similar conditions (Fig. 3c) . These data indicate that Aza-dC sensitized normal and cancer cervical cells to the pro-apoptotic effect of BzATP, probably by upregulating the expression of P2X 7 mRNA (Fig. 3a) and protein receptor (Fig. 3b) .
To determine whether apoptosis per se can stimulate an increase in P2X 7 mRNA, hEVEC and HeLa cells were incubated in serum-free medium for 14 h. The rationale was that serum deprivation increases apoptosis of cultured cervical cells [8] . The results (not shown) indicated that P2X 7 mRNA steady-state levels in hEVEC and in HeLa cells were similar in serum-deprived and in serum-exposed cells.
Modulation of DNA methylation in HEK293 cells
Effects of changes in the methylation status on P2X 7 transcription were tested more directly in HEK293 cells transfected with the luciferase P2X 7 −158/+32 or the −158/+573 reporters. Hypermethylation assays involved incubation of the test plasmids with the CpG-Methylase M. SssI prior to transfections, and de-methylation assays were done by treating transfected cells with Aza-dC. Hypermethylation had no significant effects on luciferase mRNA levels in HEK293 cells transfected either with the luciferase P2X 7 −158/+32 or luciferase −158/+573 reporters (Fig. 4) . De-methylation, induced by treatment with Aza-dC had no significant effect on luciferase mRNA levels in cells expressing the −158/+32 nt construct. However, it increased luciferase mRNA levels twofold in cells expressing the −158/+573-nt construct (Fig. 4) .
The specificity of the effects shown above was determined by measuring effects of de-methylation and hypermethylation on CK-18 and GAPDH mRNA steady-state levels. Both in hEVEC and in HeLa cells, treatment with Aza-dC had no significant effects on the steady-state levels of CK-18 and GAPDH mRNA levels (not shown). Also, in HEK293 cells transfected with either the luciferase P2X 7 −158/+32 or the −158/+573 reporters, de-methylation and hypermethylation assays did not affect significantly steady-state levels of GAPDH mRNA (not shown).
Collectively, the data in Figs. 3 and 4 suggest that regions downstream of the active P2X 7 promoter regulate transcription by modulation of DNA methylation. Fig. 3 Effects of treatments with Aza-dC (1 μM) on steady-state levels of P2X 7 mRNA (a), P2X 7 receptor protein levels (b), and BzATP-induced apoptosis (in arbitrary units [A.U.]) (c). Means ± SD of three to six experiments in triplicates. Insert in b shows immunofluorescence data (×20). Data in a and b were normalized (=1) to levels in hEVEC cells at t=0. The time-related increases in P2X 7 mRNA (a) and P2X 7 receptor protein levels (b) for both hEVEC and HeLa cells were significant (p<0.01). Protein levels of P2X 7 remained higher (p<0.01) in hEVEC than in HeLa cells throughout the length of the experiment. In c, treatments with Aza-dC were followed by 100 μM BzATP (added for 8 additional hours). The degree of apoptosis (in arbitrary units [A.U.]) was normalized to levels determined in non-treated cells. In c, *p<0.05; **p<0.01
CpGs downstream of the promoter inhibit transcription
To understand which CpG sites in the 547-nt region downstream of the promoter play a role in the regulation of P2X 7 transcription, cDNA fragments were constructed containing the active promoter (nt −158/+32) attached with one of different segments of the 547-nt region downstream of the promoter (Fig. 5a ). The cDNA fragments were inserted into a luciferase vector; the P2X 7 -luciferase reporter was transfected into HEK293 cells, and P2X 7 transcription was determined in terms of luciferase activity.
Luciferase activity in the fragment −158/+221 was low, about 10% compared to that of the active promoter alone (nt −158/+32; Fig. 5a ). Luciferase activity in the fragment −158/+232 was higher, about 75% compared to the active promoter (Fig. 5a ). Luciferase activities in fragments −158/+337 and −158/+402 were lower by 25% and 50%, respectively than in fragment −158/+232 (Fig. 5a ). Luciferase activity in fragments −158/+470 and −158/+503 was similar to that in fragment −158/+232 (Fig. 5a ). Luciferase activity in fragment −158/+573 was low, about 10% of that in fragment −158/+32 (the active promoter; Fig. 5a ).
To determine if CpG sites in the 547-nt region downstream of the promoter affect P2X 7 transcription, selected CpG sites were mutated ( Fig. 5b; Table 4 ), and the effects on transcription were tested. The following mutations resulted in a significant increase in luciferase activity: +211/+212 (CG/AA), +257/+258 (CG/TT), +278/+279 (CG/ TT), +319/+320 (CG/AT), +330/+331 (CG/AT), +424/+425 (CG/TT), +453/+454 (CG/TT), and +461/+464 (CGCG/ ATTA; Fig. 5b ). These data suggest that CpGs +211/+212, +257/+258, +278/+279, +319/+320, +330/+331, +424/+425, +453/+454, and the bi-CpG complex +461/+464 inhibit P2X 7 transcription.
CpG sites downstream of the active promoter are constitutively hypermethylated in cervical cells
The data in the cultured host HEK293 cells suggested that CpG sites in the CpG-rich 547-nt region downstream of the active promoter can modulate P2X 7 transcription through changes in their methylation status. To confirm the discovery and to understand its biological relevance, the degree of methylation of cytosines within selected CpG sites in the 547-nt region was determined in cultured normal and cancerous human uterine cervical epithelial cells, and in normal and cancerous human cervix epithelial tissues. The specific objective was to correlate cytosines methylation status with cell histology (normal versus cancer).
The control experiments are shown in Fig. 6a and b. The first experiment tested effects of treatment with Aza-dC on the methylation status of cytosines within CpG sites of the 547-nt region. cDNA segments of interest (segments 1-3) were generated from Aza-dC-treated HeLa cells and analyzed by the genomic DNA bisulfite conversion method followed by gene-specific PCR and restriction enzyme cutting. The amplified segments were cut with restriction enzymes to detect potential methylation-sensitive cytosines at CpG sites. Sites +193/+194 and or +211/+212 (segment 1), and +330/+331 (segment 2) were cut with MaeII; sites +461/+462 and or +463/+464 (segment 3) were cut with BstUI (Fig. 1) . The employed method could not differentiate between sites +193/+194 and +211/+212 due to their close proximity which could not be resolved by gel electrophoresis; or between sites +461/+462 and +463/ +464 because either could be the target of the BstUI. Figure 6a shows that treatment with Aza-dC decreased cleavage at CpG sites in all three segments. Densitometry of the data in Fig. 6a showed that the degree of cleavage at CpG sites (defined in terms of the ratio of densitometry of the cleaved band, relative to the uncleaved plus cleaved bands [%]) decreased in segment 1 from 22% to 5%; in segment 2 from 65% to 43%; and in segment 3 from 48% to 22%. These data suggest that Aza-dC induced demethylation of cytosines within CpG sites at the 547-bp region, and confirmed the validity of the method that was used.
The positive control for the experiment in Fig. 6a was human placental genomic DNA treated in vitro with the CpG-methylase SssI. Aliquots of placental DNA were mixed with different amounts of SssI and the degree of methylation was determined in terms of cleavage at CpG sites, as in Fig. 6a . The degree of methylation in the absence of methylase SssI was small (Fig. 6a) , but it increased in a dose-related manner (Fig. 6b) , relative to the amount of Sss1 versus placental DNA in the reaction mixture.
A similar method was used to evaluate the methylation status of cytosines within those CpG sites in cultured normal and cancer human cervical cells (Fig. 6c-e) , and in normal and cancer human cervix epithelial tissues (Fig. 6f-i) . The results in cultured cervical cells showed bands corresponding to fractions cleaved at those CpG sites (Fig. 6c-e) . The results also revealed greater degree of cleavage in cultured cancer cells than in cultured normal epithelial cervical cells (Fig. 6c-e) . Similar experiments were done on human cervix epithelial tissues using specimens obtained by microdissection from uterine tissue cross sections. Experiments utilized paired specimens from ten patients, including, in each case, normal and squamous cell carcinoma tissues. Sufficient amounts of tissues were available in nine cases for segments 1 and 3 and in eight cases for segment 2. The results showed bands corresponding to fractions cleaved at the above CpG sites both in cancer and in normal tissues, with a similar tendency of greater degree of cleavage in cancer tissues than in normal tissues (Fig. 6f,h) .
Semi-quantitative analysis of the data in cultured cervical cells showed a five-to tenfold-higher degree of cleaved fractions in all three segments in cancer cells than in normal cells (Table 7) , suggesting greater degree of hypermethylation of cytosines at the tested CpG sites in the cancer cells than in the normal cervical cells. Similar trends were obtained in cervix epithelial tissues in vivo. Data analysis in those tissues used the densitometry ratios of [cleaved]/[uncleaved plus cleaved] fractions in normal and cancer tissues obtained from the same patient. The results showed greater degree of cleaved fractions in cancer cases than in the corresponding normal tissues in eight of nine cases of segment 1 (p<0.05); in seven of eight cases of segment 2 (p<0.01), and in eight of nine cases of segment 3 (p<0.05p; Fig. 6i) . Collectively, the data in Fig. 6c -l suggest that in cultured cervical cells and in the cervix in vivo cytosines within CpG sites +193/+194 (and or +211/ +212), +330/+331, and +461/+462 (and or +463/+464) in the 547-bp region downstream of the active P2X 7 promoter are hypermethylated to a greater degree in cancer cells than in normal epithelial cells. Fig. 5 Elucidation of transcription regulatory cis elements within a CpG-rich 547-nt region downstream of the P2X 7 promoter. a cDNA fragments were constructed containing the P2X 7 active promoter (nt −158/+32) attached with one of the shown segments of the 547-nt region downstream of the promoter (Fig. 1) . b Effects of mutations in the CpG sites within the 547-nt region downstream of the promoter on P2X 7 transcription. WT wild-type. Mutations are described in the section of "Methods" section. For both a and b cDNA fragments composed of the P2X 7 active promoter attached with one of the shown segments were inserted into a luciferase vector and transfected into HEK293 cells. Promoter activity was determined in terms of changes in luciferase activity (Fluc/Rluc, means ± SD, of two experiments in triplicates). In a *p<0.01 compared to −158/+32; **p<0.05-0.01 compared to −158/+232. In b *p<0.01 compared to the wild-type sequence in each case Fig. 6 a Effects of treatment with Aza-dC in HeLa cells (1 μM, 48 h) on methylation of cytosines in CpG sites +193/+194 (and/or +211/ +212), +330/+331, and +461/+462 (and/or +463/+464), within segments 1, 2, and 3 respectively of a 547-nt region downstream of the P2X 7 active promoter (Fig. 1) . Methylation of cytosines in CpG sites was determined in terms of cleavage at CpG sites using the genomic DNA bisulfite conversion method followed by gene-specific PCR and restriction enzyme cutting. Left-pointing arrows show bands corresponding to uncleaved (broken lines) and cleaved fractions (continuous lines) at the CpG sites. M markers. Controls were aliquots of human placental genomic DNA (H.G.-DNA) treated in vitro with the CpG-methylase SssI. b Aliquots of human placental genomic DNA were mixed with different molar concentrations of SssI and the degree of cleavage at CpG sites +193/+194 (and/or +211/+212) within segment 1 was determined as in a. Data were normalized to the effect (100%) obtained in a reaction mixture containing 1 μg DNA. c-h Methylation status of cytosines in CpG sites in cultured human epithelial uterine cervical cells (c-e) and in human uterine cervix tissues in vivo (f-h). Experiments were done as in a, and data on the degree of the cleaved fractions (in terms of the ratio of densitometry of the cleaved, versus the uncleaved plus cleaved bands [%]) are summarized in Table 1 . i Degree of cleavage at CpG sites in tissues of human cervix. Data were compiled from ten sets of paired cervical specimens, including in each case normal and squamous cell carcinoma tissues. Available for analysis were nine cases for segments 1 and 3, and eight cases for segment 2. Experiments and data evaluation were done as above. suggest that the transcription inhibitory effects of the hypermethylated CpGs are associated with their proximity to regions that may have enhancer activity. To begin understanding the molecular mechanism of P2X 7 transcription regulation we tested the hypothesis that the putative enhancer regions nt + 222/+232 and +401/+573 in the 547-bp region downstream of the active P2X 7 promoter contain protein binding sites. To this aim, electrophoretic mobility shift assays (EMSA) were used to detect DNA-protein complexes. Using four amplified fragments (Table 5) we found one shifted band in the +217/+237 fragment; one shifted band in the +401/+530 fragment; and four shifted bands in the +401/+573 fragment (Fig. 7) . These data indicate the presence of DNA-protein complexes in the +217/+237 and the +476/+573 regions.
Discussion
The present study reports, for the first time, the TpIS of the P2X 7 gene, and defines its active promoter region. We also discovered that a CpG-rich 547-nt region downstream of the active promoter regulates transcription: regions at nt +222/+232 and +401/+573 downstream of the active P2X 7 promoter contain enhancer cis elements, while methylated CpGs located in the +33/+573 region downstream of the active P2X 7 promoter exert an inhibitory effect on transcription.
The data that a CpG-rich 547-nt region downstream of the active promoter inhibits transcription are novel in terms of epigenetic (methylation) control of transcription by cisinhibitory elements located downstream of an active promoter. Regulation of transcription by methylation of CpGs is a known epigenetic mechanism that modulates gene function [52] . However, in most genes, methylation involves the promoter, where the addition of methyl groups to the 5′ of cytosines can alter the appearance of the DNA groove to which the DNA-binding proteins bind [52] . This can modulate the spatial conformation of transcription factors recognition sites [53] , or interfere with the recruitment of proteins that function as adaptors between DNA and chromatin-modifying enzymes [54, 55] . The net effect would be modulation of the transcription machinery [56] .
Although the hypothesis that regions outside an active promoter can regulate transcription by modulation of DNA methylation is not new [51, 52, [57] [58] [59] , until recently, there have been no reports of studies that tested it directly. The present data show, for the first time, direction-dependent regulation of promoter activity by methylated CpGs located downstream of an active promoter. The conclusion that the inhibition of P2X 7 transcription imparted by CpGs within the 547-nt region involves effects of hypermethylated CpGs is supported by the data that CpGs located in the +33/+573 region are constitutively methylated; that methylation exerts an inhibitory effect on transcription; and that demethylation increases transcription. The data also identified specific CpG sites that determine the inhibitory effect. Mutagenesis of CpGs +211/+212, +257/+258, +278/+279, +319/+320, +330/+331, +424/+423, +453/+454, and the biCpG complex +461/+464 increased transcription, and each of these CpGs inhibits transcription when methylated. Moreover, the data of bisulfite restriction experiments in cultured cervical cells, and in cervix epithelial tissues in vivo, showed that cytosine within CpG sites +193/+194 Fig. 7 Elucidation of DNA-protein binding within the 547-nt region downstream of the P2X 7 promoter. cDNA fragments were constructed containing the indicated P2X 7 gene segments (Table 5) . Electrophoretic mobility shift assays (EMSA) were used to detect DNA-protein complexes. Right-pointing arrows indicate shifted bands. The experiment was repeated twice (and / or +211/+212), +330/+331, and +461/+462 (and/or +463+464) are endogenously methylated, and that the degree of methylation was greater in cancer cells than in normal cervical cells. From a functionality point of view, the data in segment 1 are relevant only to CpG +211/+212 since CpG +193/+194 had only minimal effect on transcription. Also, the effect in segment 3 involves mainly the bi-CpG +461/+464 complex because mutagenesis of both +461/+462 and +463/+464 CpGs produced the greatest effect (Fig. 5b) . It is possible that in addition to CpGs +211/+212, +330/+331, and +461/+464, cytosines at additional CpG sites within the 547-nt region downstream of the promoter are also hypermethylated in cancer cells than in normal cervical cells. However, the lack of commercially available restriction enzymes to target additional CpG sites in this unique DNA segment made it impossible to extend the study to other CpG sites. An alternative method, cloning and sequencing of representative DNA segments could yield meaningful results only if single cells are processed, but in the context of the present study, this would have become an impractical approach given the large number of cells/tissues that were needed to be processed vis-à-vis the large cell variability in cultured and intact tissues. Interestingly, the differences in methylation between the cancer and normal cervical cells correlated inversely with levels of P2X 7 expression in these cells. P2X 7 mRNA and protein receptor levels are lower in cancer cervical cells than in normal cells, both in culture and in vivo [7, [11] [12] [13] , while CpG sites +211/+212, +330/+331, and +461/+464 were hypermethylated in the cancer cervical cells compared to the normal cells (present data). In other systems, hypermethylation of genes has been associated with repression of tumor suppressor genes [60] , and has been implicated in cancer development and metastasis [51, 56, 61, 62] . DNA hypermethylation in the promoter [51] or in 5′ non-coding or coding regions [52, 57, 58] can lead to defects in DNA repair, cell cycle control, cell adherence, and apoptosis. Therefore, the correlation in cervical cancer cells between hypermethylation of cytosines in CpG sites downstream of the P2X 7 promoter and the reduced expression of P2X 7 mRNA and protein, together with the finding that those CpG sites exert an inhibitory effect on P2X 7 transcription suggest a novel mechanism of P2X 7 transcription. Accordingly, hypermethylated CpG sites +211/+212, +330/+331, and +461/+464, and perhaps additional hypermethylated CpGs within the 547-nt region downstream of the promoter, are direction-dependent inhibitory cis elements of P2X 7 transcription.
The molecular mechanism by which hypermethylated CpGs within the 547-nt region downstream of the P2X 7 promoter inhibit transcription is, at present, unknown. One possibility is by modulation of the spatial conformation of transcription factors recognition sites within the putative enhancer regions (present data). This conclusion is supported by the EMSA data which suggested the presence of four DNA-protein complexes in the +217/+237, in the +476/+530, and in the +531/+573 regions, and by the methylation assays which suggested that those regions are flanked by hypermethylated CpGs (Fig. 8) . The possibility that one or more of the four DNA-protein complexes reflect transcription factors recognition sites is supported by bioinformatics analysis of the P2X 7 gene [63] which revealed an association between the locations of the putative enhancer regions with factors known to regulate transcription of other genes. The sequence of the putative enhancer region +222/+232 matched with binding sites for p300, Elk-1, and E47. p300 promotes transcription by acetylating histones and integrating signaling from enhancer and promoter regions [64] ; Elk-1 is regulated by phosphorylation in response to activation of mitogenactivated protein kinase (MAPK) pathways [65] ; while E47 is a member of the E2 protein family encoded by the E2A gene. E47 regulates cell development and differentiation, and repression or absence of E47 activity has been implicated in cancer development [66] . Bioinformatics analysis of the sequence of the putative enhancer region +401/+573 also revealed putative binding sites for p300, Elk-1, and E47, as well for EIIaE, E2F, and p53. EIIaE and E2F are also members of the E protein family; both control cell cycle progression [67] [68] [69] , and over-expression of E2F-1 can activate apoptosis [70] . The p53 tumor suppressor transcription factor controls expression of genes involved in the regulation of cell cycle progression and cell death [71] , and there is an association between activation of the P2X 7 receptor and the p53 apoptotic pathway [72] , and between increased expression of the P2X 7 receptor and p53 protein levels [73] . Additional studies are needed to determine whether the experimentally found four DNA-protein complexes correspond with any of the above suggested transcription factors.
The present data showed that the putative enhancer +222/+232 and +401/+573 regions co-localize with, or are flanked by, constitutively methylated CpGs. The association of inhibitory CpGs with binding sites of putative enhancers suggests a novel mechanism, such that hypermethylated CpGs inhibit P2X 7 transcription by modulating the interaction of enhancer transcription factors with their cognate DNA-binding domains.
Based on these findings, we propose a novel model of P2X 7 transcription regulation (Fig. 8) . Transcription of the P2X 7 receptor is regulated by cis-enhancer elements located in nt +222/+232 and +401/+573 downstream of the active P2X 7 promoter, which contain binding sites for transcription factors. Transcription of the P2X 7 receptor is negatively controlled by methylated CpG sites +193/+194 (and/or +211/+212), +330/+331, and +461/+462 (and/or +463 +464) that flank the enhancers (Fig. 8) . Since transcription in cells expressing the −158/+573-nt construct was lower compared to that in cells expressing the active promoter (nt −158/+32), the data suggest that under baseline conditions, the effect of the putative inhibitors surpasses that of the putative enhancer(s).
The present data and previous studies in the field provide better understanding of the physiological and biological roles of the P2X 7 . The P2X 7 receptor is a pro-apoptotic mechanism that controls cell growth, but cells have devised mechanisms to regulate expression and activity of the P2X 7 receptor and to avoid death. First, enhancers of transcription downstream of the P2X 7 promoter are controlled by neighboring CpG sites in a hypermethylated state (present data). Second, P2X 7 transcripts can be degraded posttranscriptionally by the actions of micro-RNAs [13] . Third, cells produce non-functional variants of the P2X 7 receptor [11, 74, 75] that can oligomerize with the functional fulllength receptor [11] . In epithelial cells, P2X 7 -mediated apoptosis involves formation of pores that are composed of oligomers of P2X 7 molecules [11, 76] and pannexins [77, 78] , but co-expression of variants, e.g., the P2X 7-j [11] would favor formation of non-active complexes of the receptor [11] . Together, these data indicate that under physiological conditions, the P2X 7 mechanism is tightly controlled and regulated. The data also indicate that in several types of epithelia, e.g., the cervix, the expression of P2X 7 in cancer cells is reduced [7, [11] [12] [13] , suggesting that the abrogated P2X 7 -mediated apoptosis is associated with the development of cancer. At present, it is unknown whether the changes that lead to reduced expression of the P2X 7 receptor, e.g., hypermethylation of the CpGs in cancer cells, are secondary to the cancer process; or whether they precede the carcinogenic stimuli such that the abrogated apoptosis predisposes cells to the development of cancer.
In summary, the present data suggest that P2X 7 transcription is regulated by two groups of directiondependent cis regulatory enhancers located within a 547-nt region downstream of the active promoter (segments +222/+232 and +403/+573), and is controlled by the actions of CpGs that co-localize with or cluster the enhancer sites.
The experiments identified nine CpGs as inhibitory cis elements, and suggest that their effects depend on the degree of hypermethylation of the respective cytosines. Data in cervical cells elucidated three CpG sites, +211/+212, +330/ +331, and +461/+464 that are hypermethylated in cultured cells and in vivo, with greater degree of hypermethylation in cancer cells than in the normal cervical cells.
Conclusions
& P2X 7 -dependent apoptosis is an important mechanism that controls the growth of epithelial cells. & Reduced expression of the P2X 7 receptor is associated with abrogated apoptosis, and it may predispose cells to the development of cancer. & P2X 7 transcription is regulated by two groups of enhancers located within a 547-nt region (+26/+573) downstream of the active promoter. & P2X 7 transcription was found to be controlled by the action of hypermethylated cytosines at CpG sites that cluster or co-localize with the enhancers' sites. & Low expression of the P2X 7 receptor in epithelial cancer cells, e.g., uterine cervical cancer cells is determined, in part, by the inhibition of the action of transcription enhancers, located within a 547-nt region downstream of the promoter, through the action of flanking hypermethylated CpGs.
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